These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33061589)

  • 1. Real-world Data on the Efficacy and Safety of Ixazomib-based Therapy in Multiple Myeloma: A Single-center Study in China.
    Ding K; Yu H; Shao YY; Li LY; Wang CM; Song J; Li LJ; Fu R
    Cancer Manag Res; 2020; 12():8935-8941. PubMed ID: 33061589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixazomib-based maintenance therapy after bortezomib-based induction in patients with multiple myeloma not undergoing transplantation: A real-world study.
    Shen M; Zhang J; Tang R; Wang Y; Zhan X; Fan S; Huang Z; Zhong Y; Li X
    Cancer Med; 2022 Jun; 11(11):2173-2183. PubMed ID: 34655168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
    Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
    Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of total oral regimens containing ixazomib in patients with relapsed and refractory multiple myeloma].
    Wang J; Shang JJ; Jin S; Yao Y; Yan Z; Wu DP; Fu CC
    Zhonghua Nei Ke Za Zhi; 2022 Jan; 61(1):95-98. PubMed ID: 34979777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China].
    Yang Y; Xia ZJ; Zhang WH; Fu CC; Bao L; Chen B; Ding KY; Wang SL; Luo J; Li BZ; Hua LM; Yang W; Zhou X; Wang L; Xu TH; Wang WD; Wu GL; Huang Y; Li J; Liu P
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):628-634. PubMed ID: 34547867
    [No Abstract]   [Full Text] [Related]  

  • 6. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
    Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
    Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
    Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
    Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical study on ixazomib in the treatment of multiple myeloma.
    He Y; Zhang K; Zou L; Chen S; Jiang D; Hu J; Zhu Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Mar; 45(3):322-327. PubMed ID: 32386025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixazomib-based frontline therapy followed by ixazomib maintenance in frail elderly newly diagnosed with multiple myeloma: a prospective multicenter study.
    Bao L; Wang YT; Liu P; Lu MQ; Zhuang JL; Zhang M; Xia ZJ; Li ZL; Yang Y; Yan ZY; Jing HM; Dong F; Chen WM; Wu Y; Zhou HB; Fu R; Gong YP; Huang WR; Zhang YQ
    EClinicalMedicine; 2024 Feb; 68():102431. PubMed ID: 38318126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
    Xu W; Sun X; Wang B; Guo H
    Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
    Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
    J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
    Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma].
    Deng SH; Xu Y; Sui WW; An G; Mao XH; Li ZJ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):487-493. PubMed ID: 28655091
    [No Abstract]   [Full Text] [Related]  

  • 15. Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple.
    Schütz NP; Ochoa P; Duarte P; Remaggi G; Yantorno S; Corzo A; Zabaljauregui S; Shanley C; Lopresti S; Orlando S; Verri V; Quiroga L; García CA; Fernández V; Fantl D
    Hematol Oncol; 2020 Aug; 38(3):363-371. PubMed ID: 32196120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
    Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
    Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
    Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
    Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
    Kumar SK; Grzasko N; Delimpasi S; Jedrzejczak WW; Grosicki S; Kyrtsonis MC; Spencer A; Gupta N; Teng Z; Byrne C; Labotka R; Dimopoulos MA
    Br J Haematol; 2019 Feb; 184(4):536-546. PubMed ID: 30460684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy and Safety of Ixazomib-Lenalidomide-Dexamethasone Therapy for Relapsed and Refractory Multiple Myeloma].
    Takakuwa T; Araki T; Miura A; Fujitani Y; Takeoka Y; Ohta K; Yamamura R
    Gan To Kagaku Ryoho; 2019 Jun; 46(6):1043-1047. PubMed ID: 31273172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world outcomes for the treatment of relapsed/refractory multiple myeloma patients with lenalidomide-dexamethasone combinations in a Latin American country. A retrospective cohort study from
    Duarte PJ; Schutz NP; Ochoa P; Yantorno S; Orlando S; Lopresti S; Zabaljauregui S; Aizpurua F; Shanley C; Giannini E; Garate G; Foncuberta C; Milone J; Riveros D; Fantl D
    Expert Rev Hematol; 2021 Mar; 14(3):315-322. PubMed ID: 33541156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.